Enjoy complimentary customisation on priority with our Enterprise License!
The inflammatory bowel disease market size is forecast to increase by USD 7.62 billion at a CAGR of 5.48% between 2023 and 2028. The market is experiencing significant growth due to the increasing incidence of IBD worldwide and the subsequent demand for effective therapeutics. Notable new launches, such as Lilly's Mirikizumab, an oral JAK inhibitor, are revolutionizing the treatment landscape. However, the high cost of IBD therapeutics remains a major challenge, with patients and physicians seeking more affordable options. Reimbursement regulations also play a crucial role in market dynamics, with online pharmacies emerging as a potential solution for patients seeking cost savings. Despite these challenges, the market is expected to continue growing, driven by the unmet medical needs of IBD patients and the ongoing research and development of innovative therapeutic solutions.
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Distribution Channel
7 Market Segmentation by Type
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Opportunity/Restraints
11 Competitive Landscape
12 Competitive Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.
Get the report (PDF) sent to your email within minutes.